We found that the growth of UBE2T−/− MKN45 xenograft was slower and smaller than wild type or UBE2T−/− complemented with UBE2T, and Ki-67 level is lower in UBE2T−/−, whereas RACK1 level is higher in UBE2T−/− (Fig. 5H–K), suggesting that UBE2T knockout suppresses malignant progression in vivo and UBE2T is a promising target for GC therapy. Here, RACK1 is linked to gastric cancer.